Durham, NC – According to filings with the U.S. Securities and Exchange Commission, Emergo Therapeutics is raising $12,000,000.00 in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, Moise Khayrallah played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Emergo Therapeutics

Emergo Therapeutics is focused on developing drugs to modulate inflammatory cytokines and improve the functioning of the immune system in various potential indications, starting with infectious diseases.  Emergo believes that inflammation caused by mast cells, a group of cells integral to innate immunity, is responsible for some of the most damaging symptoms and outcomes of seemingly unrelated diseases. A vast majority of these conditions are not treated with mast cell therapies, even though overwhelming evidence shows this would be therapeutically beneficial.  Emergo’s therapeutic interventions are focused on reducing the production of inflammatory cytokines from mast cells.

To learn more about Emergo Therapeutics, visit http://emergotherapeutics.com/

Contact:
Moise Khayrallah, Chief Executive Officer
(984) 377-5151
https://www.linkedin.com/in/moise-khayrallah-b0894112/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved